Applied Molecular Transport is a clinical-stage biopharmaceutical company utilizing its proprietary technology platform to design and develop a pipeline of oral biologic product candidates. Co.'s proprietary technology platform allows Co. to utilize existing natural cellular trafficking pathways to facilitate the transport of diverse therapeutic payloads across the epithelial barriers. Co. has two oral biologics in clinical development. Co.'s product candidate, AMT-101, is in Phase 2 development for patients with rheumatoid arthritis. Co.'s second product candidate, AMT-126 is in Phase 1 development for diseases related to intestinal epithelium barrier function defects. The AMTI average annual return since 2020 is shown above.
The Average Annual Return on the AMTI average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AMTI average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AMTI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|